Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989;98(1):93-6.
doi: 10.1007/BF00442012.

Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats

Affiliations

Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats

M Ansuategui et al. Psychopharmacology (Berl). 1989.

Abstract

Although tricyclic antidepressants are especially useful in the treatment of chronic pain conditions, most of the work about its mechanism of action has been made on acute pain tests. The present study was aimed at studying the role played by noradrenergic and opioidergic influences on the antinociceptive activity of subchronically administered clomipramine in the formalin test (a tonic pain model) in rats. Clomipramine produced antinociception after 7 days, administration (2.5 mg/kg/day), an effect equivalent to that obtained by acute morphine (5 mg/kg). The antinociceptive effect of clomipramine was inhibited by the following: nonspecific blocking of alpha 1- and alpha 2-adrenoceptors by phentolamine, specific blocking of alpha 1-adrenoceptors by prazosin; stimulation of alpha 2 receptors by clonidine; and blocking of the opioid receptors by naloxone. Blocking the alpha 2-receptors with yohimbine did not antagonize the effect of clomipramine. These results suggest that clomipramine produces antinociception in this test, partly via the participation of the endogenous opioid system and partly by further activating or potentiating previously activated noradrenergic pathways which are involved in the control of pain information.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Rev Neurol (Paris). 1983;139(10):583-7 - PubMed
    1. Arch Int Pharmacodyn Ther. 1985 May;275(1):78-85 - PubMed
    1. Eur J Pharmacol. 1981 Aug 27;74(1):1-7 - PubMed
    1. Naunyn Schmiedebergs Arch Pharmacol. 1983 Aug;323(4):307-14 - PubMed
    1. Psychopharmacologia. 1974 Feb 27;35(3):221-36 - PubMed

LinkOut - more resources